What should be the role of homogeneity testing in adaptive trials?

Pharmaceutical Statistics

Volumn 8, Issue 1, 2009, Pages 1-4

  Gallo, Paul ^a   Chuang Stein, Christy ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL STUDY; COMPARATIVE STUDY; DECISION MAKING; EMPIRICAL RESEARCH; OUTCOMES RESEARCH; QUALITY CONTROL; SEQUENTIAL ANALYSIS; STATISTICAL ANALYSIS; SYSTEMATIC ERROR; TREATMENT RESPONSE; CLINICAL TRIAL; EDITORIAL; HUMAN; METHODOLOGY;

CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; HUMANS; RESEARCH DESIGN;

EID: 65649086704     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.342     Document Type: Article

References (7)

1. Koch A. Confirmatory clinical trials with an adaptive design. Biometrical Journal 2006; 48(4):574-585.
2. CHMP/EWP/2459/02 Reflection Paper on Methodological Issues in Confirmatory Clinical Trials Planned with an Adaptive Design. 18 October 2007. Available at: http://www.emea.europa.eu/pdfs/human/ewp/ 245902enadopted.pdf.
3. Gallo P. Operational challenges in adaptive design implementation. Pharmaceutical Statistics 2006; 5:119-124.
4. Li Z, Chuang-Stein C, Hoseyni C. The probability of observing negative subgroup results when the treatment effect is positive and homogeneous across all subgroups. Drug Information Journal 2007; 41(1):47-56.
5. Senn S. Multi-centre trials. Statistical issues in drug development (2nd edn). Wiley: New York, 2008; Chapter 14.
6. Altman DG, Royston JP. The hidden effect of time. Statistics in Medicine 1988; 7(6):629-637.
7. Friede T, Henderson R. Exploring changes in treatment effects across design stages in adaptive trials. Pharmaceutical Statistics 2008; DOI: 10.1002/pst.332.